share_log

奥本海默:维持Seres Therapeutics(MCRB.US)评级,由优于大市调整至优于大市评级, 目标价由5.00美元调整至4.00美元。

Zhitong Finance ·  May 9 12:55

奥本海默:维持Seres Therapeutics(MCRB.US)评级,由优于大市调整至优于大市评级, 目标价由5.00美元调整至4.00美元。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment